In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.
Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.
Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.
• Comparing the perspectives of industry, research and patients
• What are best practices in involving patient representatives in clinical trial design?
• What are key challenges, and how are they overcome?
• Discussing the way to go to take patient involvement to the next level
Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.
• Examples for understanding the voice of patients and sites and bringing it into clinical development
• The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
• Challenges and future opportunities
In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.
• Overview of best PE strategies across the medicines development continuum
• What we can do to improve patient recruitment and retention and some lessons learned over the COVID-19 pandemic
• Initiatives we have already implemented at Ipsen and in collaboration with our partners
• Further considerations
In 2017, the FDA approved the first-ever CAR-T cell therapy for a rare hematologic malignancy. This approval was considered a scientific revolution by many. Since then, several other gene therapies entered the market. They all come with new key characteristics - high value one-time therapies with long-term value and some even with a curative potential. This has profound implications on interactions of sponsors with patients on the one side and the whole ecosystem on the other side. This talk will give an oversight on new challenges and opportunities as well as an outlook to potential ways ahead.
• Cell and gene therapies
• CAR-T cell therapies
• Evolving patient engagement in one-time therapies
The value of incorporating patients’ insights on clinical development is now widely accepted, however, the incorporation of patient engagement in the development of new drugs is still very variable. The presentation will address this situation identifying possible reasons and possible solutions.
• The value of patient engagement on medical research
• The current situation of patient engagement
• Challenges of PE in practice
• New possibilities and examples
Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.
In 2017, the FDA approved the first-ever CAR-T cell therapy for a rare hematologic malignancy. This approval was considered a scientific revolution by many. Since then, several other gene therapies entered the market. They all come with new key characteristics – high value one-time therapies with long-term value and some even with a curative potential. This has profound implications on interactions of sponsors with patients on the one side and the whole ecosystem on the other side. This talk will give an oversight on new challenges and opportunities as well as an outlook to potential ways ahead.
The value of incorporating patients’ insights on clinical development is now widely accepted, however, the incorporation of patient engagement in the development of new drugs is still very variable. The presentation will address this situation identifying possible reasons and possible solutions.
”Excellent conference. Great discussions. The size of this conference allows for great dialogues.
Global Patient Centricity Director, Ipsen
Inside you will find
